Advertisement
Advertisement

RLMD

RLMD logo

Relmada Therapeutics, Inc. Common Stock

7.32
USD
Sponsored
-0.11
-1.48%
May 08, 15:59 UTC -4
Closed
exchange

Pre-Market

7.39

+0.07
+0.97%

Relmada Therapeutics, Inc. Common Stock Profile

About

Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neurophatic pain; BuTab ER, an oral dosage form of the opioid analgesic buprenorphine and MepiGel, a FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics Inc. is based in New York.

Info & Links

CEO

Sergio Traversa

Headquarters

2222 PONCE DE LEON BLVD. 3RD FLOOR
CORAL GABLES, FL 33134, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.relmada.com

Auditor

CBIZ CPAs P.C.

Share holders

161

Employees

17

Relmada Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

775.23M

Enterprise Value

771.73M

Enterprise Value/EBITDA(ttm)

-13.06

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

6.45

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-170.83%

Return on Invested Capital(ttm)

-269.69%

Return on Assets(ttm)

-145.58%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-59.10M

Net Income Available to Common(ttm)

-57.39M

Diluted EPS(ttm)

-1.45

Share Statistics

Beta (5Y Monthly)

0.44

52-Week Change

1644.93%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

104.89M

Dividend Yield

0.00%

Float4

83.18M

% Held by Insiders

20.70%

% Held by Institutions

45.24%

Balance Sheet

Total Cash(mrq)

93.01M

Total Cash Per Share(mrq)

0.89

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

14.62%

Quick Ratio(mrq)

14.61%

Book Value Per Share(mrq)

1.18

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.16

Free Cash Flow(ytd)

-45.79M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement